BioSante completes enrollment in LibiGel Phase 3 safety study

BioSante Pharmaceuticals (NASDAQ:BPAX) has completed enrollment in its ongoing LibiGel Phase 3 cardiovascular and breast cancer safety study. LibiGel is in development for the treatment of female sexual dysfunction, specifically, hypoactive sexual desire disorder in menopausal women, for which there is no FDA-approved product. Under the protocol, the safety study will continue for 12 months of [...]

Cytomedix submits reimbursement bid to CMS

Cytomedix (OTCBB:CMXI) has made a formal submission to the Centers for Medicare & Medicaid Services (CMS), requesting reimbursement reconsideration for autologous platelet rich plasma (PRP) gel, including the AutoloGel System. “The comprhensive request proposes that there is sufficient clinical evidence to support the conclusion that the use of autologous PRP gel for chronic, non-healing pressure ulcers and [...]

Echo’s needle-free technology a game-changer

Echo Therapeutics’ (OTCBB:ECTE) platform for needle-free drug delivery and a wireless biosensor that continuously monitors diabetics’ blood glucose levels without breaking the skin is giving the company a shot at several blockbuster markets. “The scope of the technology is applicable to the delivery of many drugs and monitoring many analytes in the blood stream,” CEO [...]

Thallion enrols first patient in high-dose Shigatec trial

Thallion Pharmaceuticals (TSX:TLN) and LFB Biotechnologies have enrolled the first of an expected 21 patients in the high-dose cohort of their Phase 2 Shigatec trial to evaluate Shigamabs as a treatment for Shiga toxin-producing E. coli (STEC) infection. The company anticipates top line results to be available prior to the end of the year. “Following [...]

Synta’s ganetespib shows activity in JAK/STAT

Results published in the on-line edition of the journal PLoS ONE (www.plosone.org) demonstrate that Synta Pharmaceuticals’ (NASDAQ:SNTA) demonstrate that ganetespib, a potent second generation inhibitor of heat shock protein 90 (Hsp90), exhibits potent in vitro and in vivo activity in a range of solid and hematologic tumor cells that are dependent on Janus-associated kinase 2 [...]

Neoprobe to sell gamma detection business

Neoprobe (AMEX:NEOP) has signed a definitive agreement to sell its GDS line of gamma detection device systems to Devicor Medical Products for $30 million in cash and a contingent value provision of up to an additional $20 million in royalties. “This transaction allows Neoprobe to strategically focus its expertise, competencies and resources in the radiopharmaceutical [...]

D. Medical’s infusion sets to be distributed in Poland

D. Medical Industries (NASDAQ, TASE:DMED) has signed an agreement for the distribution in Poland of its Spring Universal Infusion Sets, which are compatible with most insulin pumps currently available on the market. The agreement has an initial term of one year, beginning on the date of the distributor’s initial order, and will then be automatically [...]

Somaxon’s message to insomniacs: Silenor

Somaxon Pharmaceuticals (NASDAQ:SOMX) is burning the midnight oil to get its message out about the safety and efficacy of Silenor, its recently launched drug to treat insomnia. “Silenor is the first and only FDA-approved product for sleep maintenance insomnia that is not associated with risk of abuse or physical dependence,” CEO Richard Pascoe says in [...]

TearLab gets IGel reimbursement in Germany

TearLab (NASDAQ:TEAR; TSX:TLB) has received a unique, new “individual health benefits” or IGel code that applies to its osmolarity test for dry eye disease in Germany, effective immediately. IGel is the self-pay coding system that enables reimbursement for insured individuals. The system runs parallel to the state funding system and allows practitioners greater flexibility in [...]

GeneNews holders okay early warrant campaign

Shareholders of GeneNews (TSX:GEN) at the annual meeting approved an early warrant exercise incentive program to run from May 17 to June 8. If all warrants eligible to participate in the program are exercised during the 22-day period, the company expects it will receive gross proceeds of up to about $4.1-million, and issue up to [...]

Next Page »